PRTG

Portage Biotech Inc. [PRTG] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PRTG Stock Summary

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 40.22%

Top 10 Correlated ETFs

PRTG

Top 10 Correlated Stocks

PRTG

In the News

09:02 01 Apr 2023 PRTG

New Strong Buy Stocks for January 26th

FYBR, SPPJY, KMTUY, PRTG and ASML have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.

07:32 01 Apr 2023 PRTG

New Strong Buy Stocks for January 20th

NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.

10:32 01 Apr 2023 PRTG

New Strong Buy Stocks for November 1st

FFNW, PTEN, PRTG, NTNX and GAMB have been added to the Zacks Rank #1 (Strong Buy) List on November 1, 2022.

11:37 01 Apr 2023 PRTG

Does Portage Biotech Inc. (PRTG) Have the Potential to Rally 206% as Wall Street Analysts Expect?

The mean of analysts' price targets for Portage Biotech Inc. (PRTG) points to a 206.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

04:07 01 Apr 2023 PRTG

Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform

Portage Biotech Inc (NASDAQ: PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now wholly owns the worldwide rights to its small molecule iNKT agonists, including lead programs PORT-2 and PORT-3. The platform was acquired.

04:53 01 Apr 2023 PRTG

Portage Biotech to Present at the Piper Sandler 33rd Annual Healthcare Conference

WESTPORT, Conn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that Chief Executive Officer, Dr. Ian Walters, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. Dr. Walters will give an overview of Portage's pipeline and status of current programs, including the company's lead invariant natural killer T cell (iNKT) agonists, PORT-2 and PORT-3.

08:00 01 Apr 2023 PRTG

Portage Biotech Announces Participation in September 2021 Investor Conferences

WESTPORT, Conn., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company focused on the development of therapies and treatments targeting cancer treatment resistance, today announced that as part of its commitment to investor outreach, management will be participating in the following investor conferences in September 2021.

08:00 01 Apr 2023 PRTG

Portage Biotech Announces Results for First Quarter of 2022 Fiscal Year

- $29 million raised during quarter with broad institutional support

08:00 01 Apr 2023 PRTG

Portage Biotech Highlights First Patient Dosed in IMP-MEL Study of PORT-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (NSCLC)

WESTPORT, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the first patient has been dosed in the Oxford-led IMP-MEL study, a Phase 1/2, open-label, dose-escalation and randomized expansion clinical trial assessing the safety, tolerability and efficacy of PORT-2, a liposome formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 developed for the treatment of solid tumors.

09:00 01 Apr 2023 PRTG

Portage Biotech Added to Russell 2000(R) Index

Westport, Connecticut--(Newsfile Corp. - June 29, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that the Company has been added to the Russell 2000 Index at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opened on June 28. "Inclusion in the Russell 2000 index marks another key milestone for Portage,...

PRTG Financial details

Company Rating

Neutral

Market Cap

53.78M

Income

-13.68M

Revenue

Book val./share

9.92

Cash/share

0.77

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

01 Mar 2023

P/E

-3.85

Forward P/E

PEG

1.13

P/S

P/B

0.31

P/C

4.01

P/FCF

-5.94

Quick Ratio

5.75

Current Ratio

6.41

Debt / Equity

0.25

LT Debt / Equity

EPS (TTM)

-0.89

EPS next Y

EPS next Q

EPS this Y

-4.44%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

633.33%

SMA20

-24.32%

SMA50

-47.96%

SMA100

-58.27%

Inst Own

0.06%

Inst Trans

0.02%

ROA

-6%

ROE

-9%

ROC

-0.08%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

17.4M

Shs Float

9.84M

Target Price

19.5

52W Range

2.34-11.99

52W High

-71.91%

52W Low

+54.5%

RSI

45.95

Rel Volume

0.64

Avg Volume

39.58K

Volume

25.28K

Perf Week

17.49%

Perf Month

-25.18%

Perf Quarter

-53.18%

Perf Half Y

-50.48%

Beta

115.11

Volatility

0.17%, 0.43%

Prev Close

Price

3.09

Change

14.44%

PRTG Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric	2018-03-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31
Revenue per share	0	0	0	0	0
Net income per share	46.21	-0.55	-0.49	-1.35	-1.29
Operating cash flow per share	-0.4	-0.18	-0.34	-0.37	-0.52
Free cash flow per share	-0.4	-0.18	-0.34	-0.37	-0.52
Cash per share	2.83	1.3	0.29	0.24	1.79
Book value per share	3.59	20.68	8.81	8.65	9.28
Tangible book value per share	3.59	-2.52	-1.38	-1.12	0.36
Share holders equity per share	3.59	20.68	8.81	8.65	9.28
Interest debt per share	0.1	0.78	0.39	0.17	0
Market cap	20.08M	45.31M	99.66M	328.17M	85.8M
Enterprise value	12.8M	42.8M	100.17M	327.2M	62.45M
P/E ratio	0.16	-17.19	-18.69	-20.73	-5.09
Price to sales ratio	0	0	0	0	0
POCF ratio	-18.72	-52.81	-26.83	-76.6	-12.69
PFCF ratio	-18.72	-52.81	-26.83	-76.6	-12.69
P/B Ratio	2.09	0.45	1.03	3.23	0.71
PTB ratio	2.09	0.45	1.03	3.23	0.71
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	0.1	-16.81	-38.36	-24.49	-5.01
EV to operating cash flow	-11.93	-49.89	-26.97	-76.38	-9.23
EV to free cash flow	-11.93	-49.89	-26.97	-76.38	-9.23
Earnings yield	6.16	-0.06	-0.05	-0.05	-0.2
Free cash flow yield	-0.05	-0.02	-0.04	-0.01	-0.08
Debt to equity	0.04	0.25	0.29	0.27	0.24
Debt to assets	0.04	0.14	0.16	0.16	0.15
Net debt to EBITDA	-0.06	0.98	-0.19	0.07	1.87
Current ratio	59.97	3.65	1.48	1.54	31.71
Interest coverage	-69.59	-31.41	-10.73	-70.28	-362.51
Income quality	-0.01	0.33	0.7	0.27	0.35
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0.93	0.93	0.92	0.83
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	61.11	15.95	9.83	16.2	16.42
ROIC	0.43	-0.02	-0.05	-0.08	-0.14
Return on tangible assets	12.37	-0.2	-0.43	-1.12	-0.5
Graham Net	2.69	-3.91	-2.22	-2.04	-0.44
Working capital	7.49M	4.76M	1.23M	1.74M	24.05M
Tangible asset value	9.62M	-12.16M	-15.07M	-13.11M	4.72M
Net current asset value	7.23M	-18.61M	-23.74M	-22.31M	-4.4M
Invested capital	0.02	0.04	0.04	0.02	0
Average receivables	22.22K	41.5K	57.5K	371.5K	446K
Average payables	118.03K	257.5K	365.5K	228K	150.5K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	12.86	-0.03	-0.06	-0.16	-0.14
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q3

Metric	2021-09-30	2021-12-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-0.22	-0.26	-0.13	-0.06	-0.44
Operating cash flow per share	-0.1	-0.12	-0.16	-0.15	-0.16
Free cash flow per share	-0.1	-0.12	-0.16	-0.15	-0.16
Cash per share	2.04	1.92	1.59	0.9	0.77
Book value per share	9.54	9.43	9.04	10.66	9.92
Tangible book value per share	0.97	0.81	0.32	-0.7	-1.24
Share holders equity per share	9.54	9.43	9.04	10.66	9.92
Interest debt per share	0	0	0	0	0
Market cap	270.91M	143.18M	93.19M	114.18M	90.12M
Enterprise value	243.65M	117.58M	72.01M	99.14M	77.02M
P/E ratio	-22.77	-10.19	-13.47	-30.08	-3.01
Price to sales ratio	0	0	0	0	0
POCF ratio	-212.48	-86.36	-42.83	-45.45	-33.33
PFCF ratio	-212.48	-86.36	-42.83	-45.4	-33.33
P/B Ratio	2.13	1.14	0.77	0.64	0.53
PTB ratio	2.13	1.14	0.77	0.64	0.53
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-70.19	-34.64	-16.9	-28.38	-14.71
EV to operating cash flow	-191.09	-70.92	-33.09	-39.47	-28.48
EV to free cash flow	-191.09	-70.92	-33.09	-39.42	-28.48
Earnings yield	-0.01	-0.02	-0.02	-0.01	-0.08
Free cash flow yield	0	-0.01	-0.02	-0.02	-0.03
Debt to equity	0.2	0.19	0.23	0.22	0.25
Debt to assets	0.13	0.12	0.14	0.18	0.2
Net debt to EBITDA	7.85	7.54	4.97	4.31	2.5
Current ratio	21.31	41.31	11.73	11.98	6.41
Interest coverage	-475.71	-4.17K	-194.62	-405.89	-95.18
Income quality	0.43	0.47	1.34	2.32	0.36
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.81	0.82	0.83	0.87	0.9
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	6.92	7.47	5.13	3.69	9.9
ROIC	-0.02	-0.03	-0.01	-0.01	-0.04
Return on tangible assets	-0.08	-0.1	-0.05	-0.04	-0.35
Graham Net	0.22	0.1	-0.49	-1.38	-1.68
Working capital	27.3M	25.64M	21.14M	15.74M	13.11M
Tangible asset value	12.87M	10.85M	4.3M	-11.64M	-21.15M
Net current asset value	3.79M	2.03M	-4.76M	-21.55M	-26.85M
Invested capital	0	0	0	0	0
Average receivables	816K	374.5K	0	545.5K	832K
Average payables	802.5K	238.5K	0	1.68M	1.92M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.02	-0.03	-0.01	-0.01	-0.04
Capex per share	0	0	0	0	0

PRTG Frequently Asked Questions

What is Portage Biotech Inc. stock symbol ?

Portage Biotech Inc. is a VG stock and trading under the symbol PRTG

Is Portage Biotech Inc. buy or a sell ?

2 stock analysts have 2 predictions with a medium analyst target price of $19.5. The lowest prediction is $18 and the highest is $21

What is PRTG stock prediction ?

What is Portage Biotech Inc. stock quote today ?

Portage Biotech Inc. stock price is $3.09 today.

Is Portage Biotech Inc. stock public?

Yes, Portage Biotech Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 39.58K
Market Capitalization 53.78M
Employee 6
CEO Dr. Ian B. Walters M.B.A., M.D.
Headquarters Tortola,VG
IPO Date 2021-02-25
Website https://www.portagebiotech.com

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.